New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 15, 2014
07:40 EDTTHOR, HTWRHeartWare remains well positioned in LVAD market, says Leerink
Leerink attributes HeartWare's (HTWR) disappointing Q4 sales to company-specific issues and broader market weakness. The firm expects competitor Thoratec (THOR) to trade lower on the potential for LVAD market weakness, but keeps Outperform ratings on companies. Leerink still views Thoratec as well positioned in the LVAD market and sees potential catalysts in 2014.
News For HTWR;THOR From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 20, 2015
07:29 EDTHTWR, THORCanaccord would be buyers of Thoratec following favorable ISHLT
Subscribe for More Information
07:26 EDTHTWRHeartWare weakness a buying opportunity, says Canaccord
Subscribe for More Information
April 17, 2015
07:58 EDTTHORThoratec to hold an investor and analyst meeting
Subscribe for More Information
05:35 EDTTHORThoratec announces positive results from ROADMAP study
Thoratec announced results from the ROADMAP Study, or the Risk Assessment and Comparative Effectiveness of Left Ventricular Assist Device and Medical Management in Ambulatory Heart Failure Patients. For the primary endpoint, a composite of survival and functional improvement, ROADMAP demonstrated a statistically significant benefit of HeartMate II LVAD support relative to optimal medical management in ambulatory NYHA Class IIIB/IV heart failure patients. Survival in the HeartMate II group was 80% at one year, compared with 64% for medically managed patients on an as-treated basis. At one year of follow-up, 39% of patients within the HeartMate II group met the primary endpoint of survival on the original therapy along with a 75 meter increase in six minute walk test distance, compared with 21% of patients on optimal medical management, representing a statistically significant difference.
April 16, 2015
10:04 EDTTHORHigh option volume stocks
Subscribe for More Information
09:52 EDTHTWR, THORThoratec comments on HeartMate II data in ENDURANCE therapy trial
Subscribe for More Information
08:53 EDTTHOR, HTWRBofA/Merrill medical technology analysts hold analyst/industry conference call
Subscribe for More Information
05:32 EDTHTWRHeartWare achieves primary endpoint in ENDURANCE clinical trial
Subscribe for More Information
April 14, 2015
10:03 EDTTHORThoratec management to meet with Oppenheimer
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use